Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term non-GLP testing the company has decided to advance an alternative compound for its Gaucher and GBA1 Parkinson's programs. The company continues to advance all platform programs including programs for genetic and sporadic forms of neurodegeneration (Progranulin modulators), and a ra
2026-04-10 5:05 PM EDT | Sharp Therapeutics Corp.
Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to
2026-04-10 5:00 PM EDT | Sharp Therapeutics Corp.
Younet AI Partners with Perpetuals.com to License and Co-Develop Forgentiq.ai Sovereign LLM and Agentic Technology Platform
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Younet AI, the enterprise-grade private AI solutions provider, today anno
Technology, Biotechnology, Computer Software
2026-04-10 10:21 AM EDT | Younet.ai
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.
iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time
Woburn, Massachusetts--(Newsfile Corp. - April 9, 2026) - iSpecimen (NASDAQ: ISPC), an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct shipment of biospecimens from supplier sites to customers, both domestically and internationally. By reducing reliance on centralized hub processing, the new model simplifies logistics and eliminates multi-step routing. Previously, shipments often required routing through a central hub, which co
2026-04-09 4:05 PM EDT | iSpecimen Inc.
Zenith Epigenetics Provides Update on ZEN-3694 NUT Carcinoma Program
Calgary, Alberta--(Newsfile Corp. - April 9, 2026) - Zenith Epigenetic Ltd. ("Zenith" or the "Company") today held its annual general meeting of shareholders ("AGM"), during which President & CEO Donald McCaffrey provided an update to investors on ZEN-3694's clinical development program for the treatment of NUT carcinoma. Highlights from the presentation are summarized below and a replay of the entire presentation may be found her
2026-04-09 4:00 PM EDT | Zenith Capital Corp.
AtomVie Global Radiopharma to Present at The Bloom Burton & Co. Healthcare Investor Conference 2026
Hamilton, Ontario--(Newsfile Corp. - April 9, 2026) - AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing for clinical and commercial supply of radiopharmaceuticals and their worldwide distribution, is pleased to announce that they will be presenting at the Bloom Burton & Co. Healthcare Investor Conference (BBHIC) 2026, taking place at the Metro Convention Centre in Toronto,
Technology, Biotechnology, Investment Banking, Health
2026-04-09 10:00 AM EDT | Bloom Burton & Co. Inc.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The present
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-09 7:00 AM EDT | Phio Pharmaceuticals Corp.
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the voting results from its Annual General Meeting of Shareholders (the "Meeting") held on April 8, 2026. At the Meeting, a total of 93,246,234 commo
2026-04-09 7:00 AM EDT | Sernova Biotherapeutics
Conavi Medical to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi" or the "Company"), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO of Conavi Medical, will present and participate in one-on-one meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference to be held Apr
Technology, Biotechnology, Investment Banking, Health
2026-04-09 7:00 AM EDT | Bloom Burton & Co. Inc.
Marvel Biosciences Announces Proposed Convertible Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange. The Debentures will bear interest at the rate of twelve percent (12%) per annum, payabl
2026-04-08 4:30 PM EDT | Marvel Biosciences Corp.
Custom Health to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Kelowna, British Columbia--(Newsfile Corp. - April 8, 2026) - Custom Health Inc. ("Custom Health" or the "Company"), a vertically integrated, tech-enabled care platform, is pleased to announce that the Company will be participating as a presenting company at the 2026 Bloom Burton & Co. Healthcare Investor Conference. Shane Bishop, Chief Executive Officer, will be presenting and will also be hosting one-on-one meetings with investors throughout the conference.
Technology, Biotechnology, Investment Banking, Health
2026-04-08 2:10 PM EDT | Bloom Burton & Co. Inc.
Trenchant Technologies Capital Corp. Announces Unwinding of Previous Limitless Quantum Acquisition
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has entered into a share exchange agreement dated March 18, 2026 and fully executed on April 5, 2026, (the "Share Exchange Agreement") providing for the unwinding of the Company's previously announced acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collective
Technology, Banking / Financial Services, Biotechnology, Healthcare and Hospitals
2026-04-08 11:46 AM EDT | Trenchant Technologies Capital Corp.
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
New York, New York--(Newsfile Corp. - April 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the worl
2026-04-08 11:38 AM EDT | OS Therapies
American Aires Inc. Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the "Company") announces that the Company's auditors, AGT Partners LLP ("AGT"), have withdrawn and resigned as auditor of the Company, effective April 6, 2026, and will not complete the audit or issue an auditor's report on the Company's financial statements for the year ended December 31, 2025. AGT has advised that its withdrawal and resignation relate to a previously iden
2026-04-07 6:00 PM EDT | American Aires Inc.
BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon(R) Platform
New Zealand and Kingston, Ontario--(Newsfile Corp. - April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), today announced the signing of a Letter of Intent (LOI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon® automated cell therapy manufacturing platform. The collaboration bui
Biotechnology, Pharmaceuticals
2026-04-07 10:15 AM EDT | Octane Medical Group
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced that it has closed on a private placement providing up to $24 million in gross proceeds, consisting of $5.0 million in upfront funding and up to an additional $19 million upon the exercise of accompanying milestone-based warrants. The sole investors in the private placement are Perceptive Advisors and ADAR1 Capital Management. No placement agent was engaged in
Biotechnology, Pharmaceuticals
2026-04-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product
Highlights Brazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026 Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with applia
Technology, Biotechnology, Pharmaceuticals, Health
2026-04-07 7:00 AM EDT | TempraMed Technologies Ltd.
Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to com
2026-04-02 5:43 PM EDT | Sharp Therapeutics Corp.
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26 Company expects to receive approximately $2 million in non-dilutive R&D tax credits repayable to the company in cash from its U.K. subsidiary in 2H-26 Offering net proceeds, together with funds expected to be received via U.K. subsidiary, expected to provide cash runway into 2027 Company expects to receive approvals in
2026-04-02 5:15 PM EDT | OS Therapies